China Pharma Holdings (CPHI) risk factors, FY2025 10-K

Risks Related to our Business and our Industry

1. 01The commercial success of our products depends upon the degree of their market acceptance among the medical community. If our products do not attain market acceptance among the medical community, our operations and profitability would be adversely affected
2. 02If we fail to meet standards pursuant to the Drug Administration Law, the production at certain of our production lines will be suspended and our operations and profitability would be adversely affected
3. 03We may be subject from time to time to product cessations or recalls initiated by us or by the NMPA. Product cessations or recalls could impose significant costs on us and adversely affect our ability to generate revenue
4. 04If we fail to develop new products with high profit margins and our high-profit-margin products are replaced by competitors’ products, then our gross and net profits margins will be adversely affected
5. 05Our products face substantial competition. Other companies may discover, develop, acquire or commercialize products earlier or more successfully than we do
6. 06Most of our products are off-patent branded generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC which may increase the competition we face and reduce our business profitability
7. 07Our business depends in part on our well-known Helpson brand name, and if we are not able to maintain and enhance our brand recognition to maintain our competitive advantage, our reputation, business and operating results may be harmed
8. 08Reimbursement may not be available for our products, which could diminish our sales or affect our ability to sell our products profitably
9. 09The growth and success of our business depend on our ability to successfully market our principal products to hospitals and their selection in tender processes used by hospitals for medicine purchases
10. 10Our future research and development projects may not be successful
11. 11Our competitors may obtain approval for a competitive product before the product we are developing is approved. If this occurs, we may be precluded from getting approval until the competitor’s monitoring period expires and realize little to no benefit from our research and development investment
12. 12We may not be able to obtain regulatory approval for any of the new products and failure to obtain these approvals could materially harm our business
13. 13New product development in the pharmaceutical industry is time-consuming and costly and has a low rate of successful commercialization
14. 14We may not be able to successfully identify and acquire new products or businesses
15. 15We rely on distributors for all of our revenues and failure to maintain relationships with and collect payment from, our distributors or to otherwise expand our distribution network would materially and adversely affect our business
16. 16We rely on a limited number of distributors for the majority of sales of our products
17. 17Our operations may be affected if we could not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products
18. 18Our operations may be affected if we could not obtain raw materials from our current key suppliers on acceptable terms
19. 19We may not be able to effectively manage our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected by actions taken by our distributors and third party marketing firms
20. 20We have limited insurance coverage and may incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&O Insurance
21. 21Our future liquidity needs are uncertain and we may need to raise additional funds in the future
22. 22The failure to manage growth effectively could have an adverse effect on our business, financial condition and results of our operations
23. 23We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products
24. 24Power shortages, natural disasters, terrorist acts or other calamities could disrupt our production and have a material adverse effect on our business, financial position and results of operations
25. 25We cannot guarantee the protection of our intellectual property rights, and if infringement or counterfeiting of our intellectual property rights occurs, then our reputation and business may be adversely affected

Risks Related to Doing Business in China

1. 26Adverse changes in political and economic policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could reduce the demand for our services and materially and adversely affect our competitive position
2. 27The PRC legal system has inherent uncertainties that could limit the legal protections available to us
3. 28You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing original actions in the PRC against our company or our management based on U.S. or other foreign laws
4. 29As a Foreign Invested Company in China, Helpson’s ownership structure may be impacted by the foreign investment regulation and its measures in China
5. 30Because we receive substantially all of our revenue in Renminbi, which currently is not a freely convertible currency, and the PRC government controls the currency conversion and the fluctuation of the Renminbi, we are subject to changes in the PRC’s political and economic decisions
6. 31We cannot be certain that the Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially with respect to foreign exchange transactions
7. 32We are subject to the environmental protection laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations
8. 33Failure to comply with PRC regulations regarding the registration requirements for employee equity incentive plans may subject our PRC citizen employees or us to fines and other legal or administrative sanctions
9. 34U.S. regulatory bodies may be limited in their ability to conduct investigations or inspections of our operations in China25% rewritten
10. 35Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions
11. 36Restrictions contained in Chinese law on the ability of overseas securities regulators to collect information in China may deny investors in our Company the benefits of U.S. securities regulation
12. 37Our auditor, Enrome LLP, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, is headquartered in Singapore, and is subject to inspection by the PCAOB on a regular basis
13. 38Our China-sourced income is subject to PRC withholding tax under the new Enterprise Income Tax Law of the PRC, and we may be subject to PRC enterprise income tax at the rate of 25% when more detailed rules or precedents are promulgated
14. 39Our ability to distribute dividends are to large extent based on the dividends paid to us by our operating entity in China, and its ability to distribute dividends may be limited by the PRC laws
15. 40Dividends payable by us to our foreign investors and gain on the sale of our shares may become subject to taxes under PRC tax laws
16. 41We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies
17. 42The market price for our common stock may be volatile which could result in a complete loss of your investment
18. 43We may issue additional shares of our capital stock to raise additional cash for working capital; if we issue additional shares of our capital stock, our stockholders will experience dilution in their respective percentage ownership in the company
19. 44We are likely to remain subject to “penny stock” regulations and as a consequence there are additional sales practice requirements and additional warnings issued by the SEC
20. 45We are responsible for the indemnification of our officers and directors under certain circumstances which could result in substantial expenditures, which we may be unable to recoup
21. 46There is substantial doubt about our ability to continue as a going concern35% rewritten
22. 47We do not anticipate paying cash dividends on our common stock